Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old
Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old
Recruiting · NCT07204457 · Registry updated 2025-12-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old | Bacterial Infections and Mycoses, Infections, Neisseriaceae Infections, bacterial infectious disease, gram-negative bacterial infections, meningococcal infection | Recruiting | Phase 2 / Phase 3 | 2025-12-01 | NCT07204457 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| BMI Korea | 2 |
| EyeGene Inc. | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The Catholic University of Eunpyeong St.Mary's Hospital | Seoul | South Korea | 2 |